Recruiting
Mavacamten Pregnancy Surveillance Program - CV027-014
Aggiornato:
5 novembre, 2025
|
ClinicalTrials.gov.
Stampi il riassunto semplice
Dettagli della sperimentazione
-
Sesso
-
15+
Fascia d'età
-
1
Sede/i
-
Recruiting
Opzioni di trattamento
Principali criteri di idoneità
Inclusion Criteria: - Exposure to at least 1 dose of mavacamten at any time during pregnancy (from 4 months prior to conception to pregnancy outcome) and/or at any time during breastfeeding (up to 12 months of infant age or weaning, whichever comes first) - At least 15 years of age or older at the time of enrollment - Informed consent or institutional review board/ethics committee-approved waiver of informed consent Exclusion Criteria: - None